I put a lot of hope into CD17 as well. JC and her team are CD19 CAR-T experts, I am sure they could develop CD17 into an approved treatment even faster than the CD19s.
Plus the options to combine it with IMU's, hopefully approved by then Her-Vaxx and PD1-Vaxx and CF33. So many opportunities and options and all from one group.
Personally I consider CHM to increase by more multiples from here than IMU but that's just my opinion based on what both have already achieved and from today's valuation. In numbers, I think CHM is more likely to to reach $350m MC than IMU a $9b MC if we assume a 10 x increase from here.
But even if the best case scenarios play out it will take a few years which I am prepared to wait.
Maybe I shouldn't write so positively if I want my 7.1c order to get filled. So far there was always someone jumping in front of me when the kind sellers were ready to fill my order. Where are the 3.5c sp callers when needed.
GLTA
CHM Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)